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Abstract
Liver transplant for hepatitis B virus (HBV) currently 
yields excellent outcomes: it allows to rescue patients 
with an HBV-related advanced liver disease, resulting in 
a demographical modification of the waiting list for liver 
transplant. In an age of patient-tailored treatments, 
in liver transplantation as well the aim is to offer the 
best suitable graft to the patient who can benefit 
from it, also expanding the criteria for organ accep-
tance and allocation. With the intent of developing 
strategies to increase the donor pool, we set-up a 
multicenter study involving 3 Liver Transplant Centers 
in Italy: patients undergoing liver transplantation 
between March 03, 2004, and May 21, 2010, were 
retrospectively evaluated. 1408 patients underwent 
liver transplantation during the study period, 28 (2%) 
received the graft from hepatitis B surface antigen 
positive (HBsAg)-positive deceased donors. The 
average follow-up after liver transplantation was 63.7 
mo [range: 0.1-119.4; SD ± 35.8]. None Primary non-
function, re-liver transplantation, early or late hepatic 
artery thrombosis occurred. The 1-, 3- and 5-year 
graft and patient survival resulted of 85.7%, 82.1%, 
78.4%. Our results suggest that the use of HBsAg-
positive donors liver grafts is feasible, since HBV can 
be controlled without affecting graft stability. However, 
the selection of grafts and the postoperative antiviral 
therapy should be managed appropriately.
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Core tip: With the intent of developing strategies to 
increase the donor pool, we set-up a multicenter study 
involving 3 Liver Transplant Centers in Italy between 
March 2004 and May 2010. 1408 patients underwent 
liver transplantation during the study period, and 28 
received the graft from hepatitis B surface antigen 
positive (HBsAg)-positive deceased donors. None 
primary non-function, re-liver transplantation, early or 
late hepatic artery thrombosis occurred. Our results 
show that transplantation of grafts from deceased 
HBsAg positive donors is feasible and this represents a 
way to expand the donor pool, especially in the high-
endemic areas where a large proportion of patients are 
highly viremic and HBeAg positive.
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INTRODUCTION
Epidemiology of hepatitis B and hepatocellular 
carcinoma
Hepatitis B virus (HBV) prevalence is different from a 
geographical region to another (Figure 1): currently, in 
Northern Europe, United States, Canada and Australia 
it ranges from 0.1% to 2%, while in central and 
Eastern Europe, as well as in Mid East, India, Central 
and Southern America, it is between 3% and 7%. 
Finally, the highest incidence, ranging from 10% to 
20%, is registered in Africa and Easter Countries.
Notably, the incidence of hepatocellular carcinoma 
(HCC) in the same regions mirrors the prevalence 
of HBV. In Europe, Japan and North America HBV 
is responsible for 10%-15% of HCC cases, while 
conversely, in Asia and Africa, HBV is associated to 
70% of cases. According to several studies, the relative 
risk of developing a tumor is close to 100-fold in HBV 
carriers vs non-carriers[1]. 
Liver transplantation for HBV
Liver transplant for HBV currently yields excellent 
outcomes, but in 1983, before the introduction of 
HBV immune globulin (HBIg) and antiviral therapy, a 
United States National Institute of Health consensus 
conference recommended against transplant for HBV 
because of the poor outcomes from severe recurrent 
liver disease. The first studies showed HBIg and 
HBIg plus lamivudine to improve graft and patient 
survival[2]. Subsequently, successful suppression 
of HBV DNA before transplant by Adefovir resulted 
in improved pre- and posttransplant survival[3]. 
More recently, the use of the more potent antiviral 
agent, entecavir, entirely prevented post-transplant 
recurrence, even in some patients with prior 
lamivudine resistance[4]. Whereas the original protocols 
utilized a lifetime administration of HBIg to maintain 
a blood titer high enough to prevent reinfection, and 
this was supplemented with lamivudine and now more 
potent antiviral agents, newer protocols have reduced 
the time of administration of the HBIg to 1 year with 
continued antiviral administration indefinitely after, or 
even use Entecavir or Tenofovir as a single agent to 
achieve an undetectable pretransplant viral load and 
maintain this indefinitely afterward[3].
Liver transplant for hepatitis B virus (HBV) currently 
yields excellent outcomes: it allows to rescue patients 
with an HBV-related advanced liver disease, resulting 
in a demographical modification of the waiting list for 
liver transplant. In a review of the Scientific Registry of 
Transplant Recipients (SRTR) database of registrants 
to the liver transplant list in the United States from 
1985 to 2006, the overall number of registrants for 
HBV began declining after 1998 when oral antiviral 
therapy was first introduced[5]. Of the main indications 
for transplant owing to HBV (advanced liver disease, 
acute liver failure, and HCC), only HCC was increasing 
in number; registrants for advanced liver disease was 
declining most rapidly. This trend should continue; 
the data suggest that those with an early response 
to antiviral treatment with Tenofovir for acute severe 
reactivation of HBV have improved non-transplant 
survival (57% vs 13% for placebo-treated patients)[6].
However, antiviral therapy did not influence survival 
for those with acute liver failure owing to de novo HBV 
infection in a North American cohort of patients with 
acute liver failure[7]. It will likely be at least another 
decade until the incidence of HCC owing to HBV-
induced liver disease begins to significantly decline, 
and this in part will be owing to treatment of HBV (as 
well as immunization of populations that began in 
the early 1990s). Eventually the choice of treatment 
to prevent HBV reinfection must take into account 
treatment efficacy, patient adherence, and cost. 
Extended criteria for organ acceptance
The unmatched demand and supply rate between 
organs for transplantation is well known. As a 
matter of fact, we observed during the last decade 
a similar annual rate of donors in Europe and United 
States, while an increase of the “demand” for liver 
transplantation has been reported, in terms of new 
patients added in the waiting lists, longer mean waiting 
time and drop-out rate. Moreover, the lack of organs 
led to the exclusion from the waiting list of many 
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patients who can benefit from a transplant[8,9].
In an age of patient-tailored treatments, in liver 
transplantation as well the aim is to offer the best 
suitable graft to the patient who can benefit from 
it. In Europe and in the United States is estimated 
that almost 10% to 30% of patients listed for liver 
transplant dies before organ availability[8]. In the 
United States status I patients i.e., patients entering 
in the waiting list at the highest medical urgency, 
reported a 12 folds increased risk of death while on the 
list compared with those entering at the two lowest 
categories of urgency[10]. Data from Scandinavia 
between 1990 and 2001 show that the mortality rate 
among patients waiting for liver transplant was 16%, 
while 27% of patients listed for a highly urgent liver 
transplantation failed to get the graft[11].
For many patients with a severe clinical status 
needing urgent transplant, the so-called marginal 
organ donor can provide a chance of cure. Patients 
that never obtained a transplant due to their clinical 
characteristics may as well benefit from a marginal 
donor, overcoming the problem of organ shortage.
The terms extended donor or expanded donor 
(ECD) mean changes in donor acceptability criteria, 
which not justifies the negative connotations of these 
terms. Although criteria to select organs for donation 
were revised and modified over years, this evolution 
did not affect neither patients’ nor organs’ survival. 
Characteristics of donor and recipient, together with 
allocation scheme, organ procurement and transplant 
procedure define the “ideal organ”. Moreover, marginal 
donors can allow to obtain comparable survival rates 
when an appropriate allocation is ruled out.
Criteria and terms for certified suitability of organ 
donors: Assumptions and operational strategies in Italy
In 2001 a national commettee of experts nominated 
by the Italian National Transplant Centre (Centro 
Nazionale Trapianti-CNT) released a document for 
all personnel involved in the evaluation process of 
potential organ donor. The Commettee was made up 
of infectious disease experts, immunologists, clinical 
experts, surgeons, coordinators, anatomopathologists, 
medical examiners and oncologists. During the 
preparation phase, which lasted one year, the text 
underwent a series of changes and supplements, 
resulting in a final version shared with the scientific 
community and approved by the Italian National 
Transplant Centre as technical annex (guidelines) to 
the Ministry Decree of August 2, 2002[12]. 
These Guidelines focus on two main aspects: (1) 
The definition of acceptable/unacceptable risks for 
donor suitability or single organ utilization; and (2) the 
establishment of practical steps for the risk evaluation 
process.
The first aim was to identify the different risk levels 
and as a result five risk levels have been defined: (1) 
unacceptable risk; (2) increased but acceptable risk; 
(3) calculated risk; (4) not assessable risk; and (5) 
standard risk.
Unacceptable risk: The donor classified under this 
category should be excluded from donation and no 
organ can be used for transplantation. For example, 
HIV1 or 2 positive donors fall into this category, as well 
as HBsAg and HDV contemporaneous seropositivity. 
Neoplastic diseases represents an unacceptable risk 
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Figure 1  Geographic distribution of chronic hepatitis B virus infection-worldwide (2005). For multiple countries, estimates of prevalence of hepatitis B surface 
antigen (HBsAg), a marker of chronic hepatitis B virus infection, are based on limited data and may not reflect current prevalence in countries that have implemented 
childhood hepatitis B vaccination; prevalence may vary within countries. Source: Centers for Disease Control and Prevention (http://www.cdc.gov).
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recipient is not co-infected by delta virus; and (3) the 
patient follow-up can be monitored on the basis of a 
common national protocol established by the National 
Transplant Centre and to record data on a National 
Registry.
HBsAg negative donor: If the recipient is HBsAg 
negative, he has no anti-HBV antibodies or has a 
protective anti-HBsAg titre (≥ 10 mUI/mL), trans-
plantation can be performed, after informed consent, 
when the following conditions are met: (1) the donor 
has a negative HDV antigen, negative IgM anti HDV 
antibodies, negative IgG anti HDV antibodies or with a 
titre < 1:100 or below the significant level according to 
the used assay; and (2) the patient follow-up can be 
monitored on the basis of a common national protocol 
established by the National Transplant Centre and to 
record data on a National Registry.
As a supplement to these measures, the Italian 
National Transplant Centre has deemed as proper to 
support further transplant network health workers, 
through adhoc developed information tools and an 
expert task force (second opinion) for evaluation of 
doubtful cases.
Study design
With the intent of developing strategies to increase the 
donor pool, we set-up a multicenter study involving 
3 Liver Transplant Centers in Italy: the Universities of 
Modena, Bologna and Padova. The study was approved 
by the institutional review boards at each center. 
Patients undergoing liver transplantation between 
March 2004, and May 2010, were retrospectively 
evaluated. Among 1408 patients who underwent 
liver transplanation during the study period, 28 (2%) 
received the graft from HBsAg-positive deceased 
donors. All subjects were informed of the possible 
risks, consented to enter the study and signed a 
written form. For each HBsAg case we collected 
general clinical features and data regarding the 
transplantation, including MELD score and ischemia 
time. Then we retrospectively analyzed post-operative 
data, namely immunosuppressive therapy, histological 
evidence of HBV recurrence and antiviral therapy, and 
episodes of acute rejection. 
The Italian regulations issued by the CNT allow 
HBsAg positive HDV negative recipients, HBcAb 
positive HDV negative patients, and HBV negative 
subjects with severe end-stage liver disease and a low 
life expectancy, to receive grafts from HBsAg positive 
HDV negative donors. Liver biopsy during organ 
procurement drives the evaluation on graft status, 
together with the serovirological complete assessment 
of HBV and HCV status, including HBV DNA. Moreover, 
Ishak score ≤ 1 and low inflammation, together HDV 
negative test in both donor and recipient, are required. 
HBV viral load, liver function test and age are not 
considered as exclusion criteria.
We performed liver biopsies routinely pre- and 
with the following exceptions: carcinoma in situ, basal 
cell carcinoma, cutaneous squamous cell carcinoma 
without metastases, carcinoma in situ of the cervix, 
carcinoma in situ of vocal cords, urothelial papillary 
carcinoma (T0 according to the TNM classification). 
Eventually, systemic infections caused by agents for 
which treatments are not feasible and documented 
prior disease must also be considered as exclusion 
criteria.
Increased but acceptable risk: This category 
includes organs that can be used in case of urgency 
or particular clinical conditions of recipients. In these 
cases, even when the evaluation process shows the 
presence of pathogens or transmissible disease, 
organ utilization is allowed in the light of a risk benefit 
assessment. Patients struck by fulminant hepatitis, or 
retransplants for liver primary non function, or patients 
who underwent hepatectomy for trauma with complete 
organ function loss are included in this category. 
Calculated risk: Includes all cases where the 
presence of a specific pathogen or a serological status 
of the donor (HBsAg+, or anti-HCV+ or HBcAb+) is 
compatible with transplantation recipients with the 
same disease or serological status, independently from 
recipient’s health conditions. 
Not assessable risk: Includes cases for which the 
evaluation process does not allow an appropriate 
risk assessment for transmittable diseases for lack 
of one or more assessment elements (e.g., failure to 
collect an accurate medical history for lack of relatives, 
unavailability of microbiology data despite a well-
grounded suspicion of infectious pathology). 
Standard risk: Includes cases for which the eva-
luation process did not identify any risk factor for 
transmittable disease. It is the most frequent condition 
in the assessment of donors and grafts. 
The national guidelines also identify some special 
conditions that concern two main aspects, namely 
neoplastic and infectious risks.
About infections, special attention should be paid to 
the following cases: donor with HCV infection; donor 
with HBV infection (HBsAg positivity); donors with 
anticore IgG antibodies against B virus (HBcAb). In 
such cases the guidelines impose the adoption of the 
following procedures. 
HBsAg positive donor: If a donor turns out to be 
HBsAg positive, transplantation is allowed in a HBsAg 
positive recipient, after informed consent, provided 
that the following conditions are met: (1) the donor 
has a negative HDV antigen, negative IgM anti HDV 
antibodies, negative IgG anti HDV antibodies or with a 
titre < 1:100 or below the significant level according 
to the assay used; the absence of IgM anti HDV does 
not exclude delta virus chronic infection; (2) the liver 
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postperfusion in all cases. All the centers performed 
a liver biopsy protocol at months 6 and 12. However, 
all centers performed liver biopsies whenever 
biochemical or clinical signs of liver dysfunction 
became evident.
There was agreement on the definition of HBV 
recurrence as the contemporary presence of serum 
HBV-DNA and graft histology with evidence of lym-
phocytic infiltrates suggestive of recurrent HBV 
infection. An experienced pathologist is required for 
this evaluation, in order to avoid confusion with acute 
cellular rejection signs, like absence of endothelitis and 
cholangitis. Ishak score and the Knodell modified HAI 
were used to stage the disease, giving to each biopsy 
a HAI inflammatory grade (scale of 0-18), a fibrosis 
stage (scale of 0-6), and a total score combining the 
previous 2. Steatosis score was recorded as none (0%), 
mild (1%-30%), moderate (31%-60%), or severe 
(61%-100%), according to the degree of steatosis 
noted in the biopsy.
We performed a standard antiviral prophylaxis in all 
patients, independently from serovirological profile. 
All HBsAg-positive recipients were on antiviral 
treatment with nucleos(t)ide analogues before liver 
transplantation and continued the same antiviral therapy 
with the addition of HBV-specific immunoglobulins 
(HBIg) after liver transplantation. The HBsAg-negative 
recipients began a similar combined treatment after LT, 
with lamivudine (LMV) and HBIg. 
HBIg administration consisted of 10000 IU during 
the anhepatic phase, then 5000 IU every day for the 
first month, subsequently 5000 IU weekly for the 
second month and finally 5000 IU every 3-4 wk to 
maintain an anti-HBs titre above 250 IU/mL. This is 
the standard regimen of the transplant centers and it 
is applied even to HBV patients receiving an HBsAg-
negative graft. Tacrolimus administration in the post-
operative setting was adjusted to maintain a plasma 
concentration between 5 and 12 ng/mL. Steroids were 
started at a dose of 20 mg daily, then tapered down 
and discontinued within 6 mo.
Statistical analysis
We reported continuous data as mean ± SD, and then com-
pared those data by using the 2-side Student’s t test. 
The χ2 test with Yates’ correction, or Fisher’s exact test 
when appropriate, was used to compare groups for 
categorial variables. Survival of grafts and patients 
were evaluated using the Kaplan-Meier method 
and compared with the log-rank test. The statistical 
significance was accepted for P < 0.05. All the 
statistical analysis were performed using SPSS© 19.0.
DISCUSSION
Recipient characteristics
Four out of 28 recipients were female (median age at 
liver transplantation: 57.6 years, range: 26-67). Data 
were collected from liver transplantation until the last 
follow-up visit and the average follow-up after liver 
transplantation was 63.7 mo (range: 0.1-119.4; SD 
± 35.8). Recipient characteristics were reported on 
Tables 1 and 2.
HBV related cirrhosis, with or without HCC, was the 
indication for liver transplantation in 27 patients (Table 
1), while 1 patient was transplanted due to secondary 
biliary cirrhosis. 
The five HBsAg-negative patients showed se-
rological evidence of past HBV infection. The MELD 
score (Model of End Stage Liver Disease) was applied 
to stage their liver disease status. In case of HCC, an 
extra score based on HCC stage was added, according 
to the centre (or regional) allocation policy.
Patients were transplanted after an average of 452 
d on waiting list (range: 37-1962; SD ± 394) and at 
the time of liver transplantation presented an average 
MELD biochemical score of 15.6 (range: 7-33; SD ± 
6.5) and an average MELD score correction (depending 
from other clinical variables) of 26.8 (range 11-39; SD 
± 7.2). 
The median body mass index (BMI) at the time LT 
was 25.3 (range: 19-34; SD ± 3.2).
Nineteen patients had hepatocellular carcinoma 
(67.9%) with 13 cases (68.4%) resulting within 
the Milan criteria, whereas 6 patients (31.6%) were 
outside Milan and inside UCSF criteria.
Table 1 describes different downstaging treatments 
for each patient.
The UNOS status was 2A in 5 patients (17.8%), 2B 
in 15 patients (53.6%), and 3 in 8 patients (28.6%).
Donor characteristics
Donor characteristics were reported on Table 3 and the 
overall serological state of the recipient/donor is shown 
in the Table 4.
The median age was 52.6 years (range: 13-79, 
SD ± 16.9). 13 donors were female (46.4%) while 
15 donors were male (53.6%). The death causes are 
reported on the Table 3. The average body mass index 
(BMI) of donors was 25 (range: 19.5-29.4; SD ± 2.6) 
All the patients were HBsAg-positive. 21 donors (75%) 
were HBV-DNA positive while 7 (25%) were HBV-DNA-
negative. 2 (7.1%) donors were anti-HCV positive but 
both were HCV-RNA negative. 
None was HDV co-infected. Five patients (17.9%) 
were HBsAg negative, and 4 (14.3%) were HCV co-
infected (Table 4).
Data on pre-perfusion histologic features of the 
biopsies are shown in Table 3. Most of the HBsAg 
positive grafts had a HAI inflammatory grade between 
0-2 (71.4%), followed by an HAI inflammatory grade 
between 3-4 (28.6%). None of the grafts used had an 
HAI inflammatory grade score ≥ 5. 
In particular, 6 donors (21.4%) had a grading score 
0; 7 donors (25%) had a grading score 1; 7 donors 
(25%) had a grading score 2; 4 donors (14.3%) had 
a grading score 3; 4 donors (14.3%) had a Grading 
score 4. All the grafts had a fibrosis stage ≤ 1. 
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For 14 (50%) grafts the staging was 0. Macrostea-
tosis of the grafts are reported on the Table 3.
Operative factors
Cold ischemia time was in an average of 429 min 
(range: 255-632) and the warm ischemia time (WIT) 
was around 39.7 min (range: 30-55). The average 
hematic loss was 2307 mL (range: 300-13000). The 
mean length of stay in the Intensive Care Unit (ICU) 
was 5.5 d (range: 0-22), while the average Hospital 
stay was 21.4 d with a range from 6 to 143. 
Clinical outcome
None primary non-function (PNF), re-LT, early or 
late hepatic artery thrombosis occurred after liver 
transplantation.
Two (7.1%) patients who received an HBsAg-
positive donor liver had acute cellular rejection with a 
total of 1 event respectively for each patient.
Biliary complication occurred in seven patients 
(25%); in particular five biliary stenosis and two biliary 
leakages.
Five patients (17.9%) developed a major infection, 
2 patients (7.1%) had an Hepatitis C recurrence.
Recurrence of HBV infection, confirmed his-
tologically, occurred in 4 (14.3%) patients who 
received HBsAg positive grafts. The mean time of 
onset of HBV recurrence was 2.1 (± 1.4) mo.
The average follow-up was 63.6 mo (range: 
0.1-119.4). The 6 deceased patients died not for 
the Hepatitis B recurrence but for different reasons. 
In particular, the cause and time of death were 
respectively: 1 patient for severe sepsis (0.4 mo), 1 
patient for cardiac arrest (0.1 mo), 1 patient for HCV 
recurrence (11.8 mo), 2 patients for HCC recurrence 
(3.5 and 13 mo, respectively) and one patient for 
Merkel cell carcinoma (45 mo).
The 1-, 3- and 5-year graft and patient survival 
resulted of 85.7%, 82.1% and 78.4% (Figure 2).
Read-out
Liver transplantation is an established therapeutic 
modality for patients with end-stage liver disease 
or/and hepatocellular carcinoma. However, in recent 
years the number of patients needing a transplant 
increase overcoming the supply: as a result, the mean 
waiting time is now longer than before, with higher 
mortality rates of patients waiting for an organ. It is 
estimated that 15% to 20% of patients on the waiting 
list die each year without receiving a suitable organ. 
Several strategies have been developed by 
transplant physicians to face this increased demand: 
innovative ways of expanding the donor pool are the 
use of split and live donor LT. Another approach is the 
use of organs from “less-than-perfect donors”, also 
called “suboptimal donors”. Non-heart-beating donors 
Table 1  Recipient characteristics at the time of liver transplantation
Case Age Gender AB0 BMI Indication Real 
MELD
MELD 
correct
UNOS Wating 
List(d)
Year LT HCC criteria Downstaging type 
(No.)
1 62 M 0 27 HCC/HBV 26 36 2A     37 2007 MILAN IN LOC(1)1
2 65 M B 21 HCC/HBV 16 39 3   522 2007 MILAN IN LOC(1) + SUR(1)
3 54 M A 22 HCC/HBV 10 33 3   513 2007 MILAN IN LOC(1)
4 45 M A 24 HCC/HBV 14 34 2B   419 2007 MILAN OUT LOC (3)
5 62 M 0 29 HCC/HBV 12 33 3   445 2008 MILAN OUT LOC (2)
6 53 M 0 28 HCC/HBV 12 35 2B   515 2008 MILAN IN LOC (1)
7 45 M A 23 HCV/HBV 24 24 2A   101 2005
8 64 M B 27 HBV/HCV 33 33 2A   478 2005
9 26 M A 23 HBV 23 23 2B   742 2005
10 64 M A 22 HCC/HBV 11 23 2B   144 2005 MILAN IN LOC (2)
11 65 F B 25 HCC/HBV 12 24 2A   195 2006 MILAN IN LOC (2)
12 56 M A 24 HCC/HBV 10 24 2B   217 2006 MILAN OUT LOC (5)
13 61 F 0 23 HCC/HBV 14 30 2B   352 2006 MILAN IN LOC (2)
14 59 M A 24 HBV 30 30 2B   118 2007
15 48 F A 27 CBS 21 33 2A     82 2007
16 65 M A 24 HCC/HBV   8 25 2B   358 2009 MILAN IN LOC (2)
17 57 M A 30 HCC/HBV 14 39 2B   576 2009 MILAN OUT LOC (7)
18 55 M B 28 HCC/HBV 18 26 2B     38 2009 MILAN IN LOC (3)
19 65 M A 24 HCC/HBV   7 25 2B   371 2009 MILAN IN LOC (3)
20 63 M A 28 HCC/HBV 16 25 2B 1962 2010 MILAN IN LOC (2)
21 60 M A 34 HCC/HBV 10 27 2B   330 2010 MILAN OUT LOC (1) + SUR (1)
22 61 M A 24 HBV 11 11 3   855 2010
23 67 M 0 19 HBV 16 16 2B   742 2004
24 55 M A 24 HBV 17 17 3   127 2004
25 60 F 0 29 HBV/HCV 17 17 2B   961 2004
26 55 M A 26 HCC/HBV 10 20 3   748 2005 MILAN IN LOC (1)
27 54 M A 27 HCC/HBV 13 19 3   134 2006 MILAN OUT LOC (2)
28 67 M 0 22 HCC/HBV 12 29 3   575 2009 MILAN IN LOC (1) + SUR (1)
1LOC: Locoregional therapy [transcatheter arterial chemoembolization (TACE) and/or radiofrequency ablation (RITA)]. SUR: Surgery; MELD: Model for end-
stage disease; BMI: Body mass index; LT: Liver transplantation; HCC: Hepatocellular carcinoma; CBS: Secondary biliary cirrhosis; HCV: Hepatitis C virus.
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and donors older than 65 years belong to such donors, 
as well as steatosic liver allografts and patients with 
previous exposure to HBV or HCV. Also the selection 
HBsAg positive donors represents a way to expand the 
pool of transplantable grafts.
On the other hand, living donor (LD) LT was 
adopted in Eastern countries to counterbalance the 
lack of deceased donors due to cultural reasons. Living 
donors and split liver transplantation have been used 
to contrast the donor shortage, but they have failed to 
significantly decrease the number of patients on the 
wait list. Those two approaches have ethical issues 
and technical complexities that make them less than 
ideal ways to expand the donor pool[13-15]. In addition, 
living donor programs have been activated in a small 
minority of transplant centers, and more institutions 
have been forced to resort to the use of other marginal 
organ donors. 
As a matter of fact, wider acceptance criteria can 
assure more donors available for transplantation and 
several guidelines are available to classify donors as 
standard or ECD[16-20]. Two main categories of ECD can 
be identified: the first one includes grafts with risk of 
dysfunction due to direct or indirect liver injury, the 
second accounts for the risk of disease transmission 
between donor and recipient. 
In the first case should be taken into account 
that those grafts must be carefully evaluated and 
transplanted in recipients capable to overcome the 
increased physiologic stress.
The ECD liver disease transmission risk is broken 
into 2 separate categories: (1) viral transmission of 
HCV, HBV, HTLV-1, and HTLV-2; and (2) malignancy 
transmission. Our previously reported results are 
consistent with other studies showing that it is safe 
to allocate grafts from HCV positive donors into HCV 
positive recipients[21-25]. The HCV positive donor liver 
must have no evidence of cirrhosis or stage > 1 
fibrosis. It is clear that HCV-positive livers should be 
declassified as ECDs.
HBV scenario: About 2 billion people have serological 
evidence of present or past HBV infection worldwide, 
and a prevalence of more than 350 million cases of 
chronic infection is estimated[26].
The selection criteria of the recipient of HBcAb-
positive donors are currently debated, while it has 
been demonstrated that a lifelong antiviral therapy is 
needed after transplantation of those grafts[23,27,28]. The 
majority of chronic HBV infections is nowadays present 
in the Western Pacific region[29], while a recent survey 
from Korea showed an overall HBsAg prevalence of 
3.7%. This group of ECD is currently underestimated 
due to the high risk of HBV reactivation and to the 
paucity of clinical data, and up-to-now they are not 
used in most of the transplant centers.
Because of the existing shortage of organs, the 
increased demand for LT, and given the possible 
implications in terms of extension of the donor pool, 
the use of HBsAg-positive grafts should be studied 
to assess safety policies. To date, only a few studies 
exist regarding the effect of donor HBsAg positivity 
on survival (Table 5). These available reports yield 
conflicting results and are limited by small sample 
sizes and short follow-up[30-38].
Gonzalez-Peralta et al[31] were the first to report 
a successful LT of an HBsAg-positive graft into HBV 
negative recipient, who shortly afterwards turns 
HBsAg positive. Several reports in literature attested 
Table 2  Recipient characteristics  n  (%)
Recipient variables n  = 28
Transplant center (No. of patients)
   Modena   6 (21.4)
   Bologna 16 (57.1)
   Padova   6 (21.4)
Gender
   Male 24 (85.7)
   Female   4 (14.3)
AB0 blood group
   Isogroup 28 (100)
   0 7 (25)
   A  17 (60.7)
   B    4 (14.3)
Age (yr), mean (range, SD)   57.6 (26-67, ± 8.7)
Body mass index, mean (range, SD)   25.3 (19-34, ± 3.1)
Real MELD score, mean (range, SD) 15.6 (7-33, ± 6.5)
Correct MELD score, mean (range, SD)   26.7 (11-39, ± 7.2)
UNOS status
   2A   5 (17.5)
   2B 15 (53.6)
   3   8 (28.6)
Time waiting list (d), mean (range, SD) 452 (37-1962, ± 393.5)
Associated hepatocellular carcinoma 19 (69.7)
   Meeting Milan criteria 13 (46.4)
   Meeting UCSF criteria   6 (21.4)
HBsAg status
   Positive 23 (82.1)
   Negative   5 (17.9)
HBV DNA positive at LT 12 (52.1)
HCV co-infection   4 (14.3)
HDV co-infection 0
UCSF: University of California, San Francisco; LT: Liver transplantation; 
HCV: Hepatitis C virus; HDV: Hepatitis D virus; MELD: Model for end-
stage disease.
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Figure 2  Patient and graft survival. LT: Liver transplantation.
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the use of HBIg and antiviral drugs against HBV such 
as lamivudine, adefovir dipivoxil, and tenofovir in 
recipients with HBsAg-positive grafts[30,32-36,38]. Loggi 
et al[37] reported a series of 10 HBsAg-positive grafts 
with HBIg and nucleos(t)ide analogue prophylaxis. 
In their experience only one patient died due to HCV 
recurrence over a mean follow-up period of 36.8 mo. 
In a cohort with 8 patients out of 10 positive for HBsAg 
after LT, no patient ever had any signs of active HBV 
hepatitis.
However, there was no comparison of outcomes 
between HBsAg-positive graft recipients with and 
without HBIg prophylaxis.
Using comprehensive clinical data from the SRTR 
database, Li et al[39] failed to identify any significant 
association between the use of HBsAg-positive donors 
and post-transplant graft or patient survival, after 
adjusting for other predictors of post-transplant survival. 
Their results demonstrate that HBsAg-positive donors 
for liver transplantation are safe and comparable in 
terms of outcomes and long-term survival to the use 
of HBsAg-negative grafts. Furthermore, other studies 
clearly showed that using HBIg may improve post-
transplant survival in recipients with HBsAg-positive 
grafts.
Several innovations have been introduced during the 
last two decades to improve the outcomes of patients 
receiving LT for HBV-related liver disease, such as 
the administration of HBIg since the early 1990s and 
lamivudine in late 1990s[40-45]. Although there is now a 
consensus in favor of the use of HBIg in HBV-positive 
recipients, its application in HBV positive donors is still 
unclear.
Our study shows that the use of HBsAg positive grafts 
is a safe procedure when carried out in combination with 
appropriate antiviral therapy and when the graft fibrosis 
is ≤ 1 and the grading score is ≤ 4.
The 4 Hepatitis B recurrences that we have followed 
during the post-LT didn’t influence the graft and patient 
survival. From our own experience, there were no cases 
of PNF and the infectious and biliary complications were 
similar to the cases of HBsAg negative graft recipients. 
However, our research shows some relevant 
limitations: first, even if it represents the major 
European study, the number of patients is still too low 
and therefore it doesn’t allow to establish ultimate 
conclusions. Then, we have chosen to focus only on 
a descriptive kind of analysis while for the future it 
will be necessary to perform comparative studies and 
matched analysis. Second, the lack of a common 
serial protocol hepatic biopsies has not allowed to 
examine the histological evolution of these grafts as 
well as a serial protocol for the dosage of the HBsAg 
quantification and the HBV-DNA level.
CONCLUSION
Despite the small number of cases, our results suggest 
Table 3  Donor characteristics
Case Age Gender AB0 Gr. BMI 
(kg/m2)
Cause of 
death
Time ICU 
(d)
Sodium 
(mEq/mL)
Vasopressors Histologic activity index Graft steatosis 
macroGrading Staging
1 59 M 0 26 CH   2 165 No 1 0 20%
2 13 F B 19 T 21 161 Yes 2 0   0%
3 69 M A 24 CH   3 152 No 0 0   0%
4 72 F A 27 CH   7 150 No 1 0 35%
5 66 M 0 22 CH   5 137 Yes 3 1   0%
6 60 M 0 26 CH   4 158 No 2 0   0%
7 73 M A 26 CH   2 151 Yes 2 1   0%
8 51 M B 23 CH   6 149 Yes 3 1 10%
9 54 M A 24 T 13 160 Yes 2 1 10%
10 72 F A 23 T   2 148 No 2 0   0%
11 60 F B 29 CH   8 162 Yes 3 1   5%
12 65 M A 29 CH   3 140 Yes 4 1 30%
13 50 M 0 24 CH 12 141 Yes 2 1   3%
14 48 M A 23 T   2 143 No 4 1   5%
15 26 M A 23 T   1 145 Yes 1 0   0%
16 52 F A 28 CH   1 155 Yes 4 1   0%
17 79 F A 24 CH 19 136 No 0 0   0%
18 46 F B 29 CH   2 158 No 0 0   0%
19 61 M A 29 CH   3 156 No 1 1 10%
20 53 F A 25 CH   6 154 Yes 2 1   4%
21 44 F A 24 CH   6 144 Yes 4 1   5%
22 23 F A 21 other   7 149 Yes 1 1   0%
23 57 F 0 24 CH   4 147 Yes 0 0   0%
24 59 M A 24 CH   1 160 Yes 0 0   5%
25 35 F 0 23 CH   1 140 Yes 1 0   0%
26 36 M A 25 T   2 146 Yes 3 1   0%
27 23 M A 29 T   2 147 Yes 0 0   0%
28 66 F 0 27 CH   3 151 Yes 1 0 10%
BMI: Body mass index; CH: Cerebral hemorrhage; T: Trauma; ICU: Intensive care unit.
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that the utilization of grafts from deceased HBsAg 
positive donors, according to our allocation criteria, is 
feasible and HBV can be controlled with graft stability 
if selection of grafts and postoperative antiviral 
treatment are appropriately managed. 
This way it could be possible to expand the donor 
pool, especially in the high-endemic areas where a 
large proportion of patients are highly viremic and 
HBeAg positive.
Long-term follow-up data and large-scale mul-
Table 4  Serological state of the recipient/donor
Case HBsAg HBsAb HBcAb HBeAg HBeAb HBV DNA HDV HDV RNA HCV Ab Therapy pre-LT Mutation
R1 + - + - + - - - - Lam No
D1 + - + - + + - - - No -
R2 + - + - + - - - - Lam No
D2 + - + - + + - - - No -
R3 + - + - + + - - - Lam + Adef Yes
D3 + - + - + + - - - No -
R4 + - + + - - - - - Lam No
D4 + - + - + - - - - No -
R5 + - + - + + - - - Lam + Adef Yes
D5 + - + - + - - - - No -
R6 + - + - + - + - - Lam No
D6 + - + - + + - - - No -
R7 - + + - - - - - + No No
D7 + - + + - + - - + No -
R8 - + + - - - - - + No No
D8 + - + - + + - - - No -
R9 + - + + - + - - - Lam No
D9 + - + + - + - - - No -
R10 + - + - + - - - - Lam No
D10 + - + + - + - - - No -
R11 - + + - - - - - + No No
D11 + - + + - + - - + No -
R12 + + + - + + - - - Lam No
D12 + - + - + + - - - No -
R13 + - + - + - - - - Lam No
D13 + - + + - + - - - No -
R14 + - + - + + - - - Lam No
D14 + - + - + - - - - No -
R15 - - + - + - - - - No No
D15 + - + - + + - - - No -
R16 + - + - + + - - - Lam No
D16 + - + - + + - - - No -
R17 + - + - + + - - - Lam + Adef Yes
D17 + - + + - + - - - No -
R18 + - + - + + - - - Lam No
D18 + - + - + - - - - No -
R19 + - + + - + - - - Adefovir No
D19 + - + + - + - - - No -
R20 + - + - + + - - - Lam + Adef No
D20 + - + + - + - - - No -
R21 + - + - + - - - - NA No
D21 + - + + - + - - - No -
R22 + - + - + - - - - Lam No
D22 + - + + - + - - - No -
R23 + - + - + - - - - Lam No
D23 + - + - + - - - - No -
R24 + - + - + + - - - Lam Yes
D24 + - + - + - - - - No -
R25 - + + - + - - - + No No
D25 + - + - + - - - - No -
R26 + - + - + - - - - Lam No
D26 + - + + - + - - - No -
R27 + - + - + - - - - Adef Yes
D27 + - + - + + - - - No -
R28 + - + - + - + - - Lam No
D28 + - + + - + - - - No -
R: Recipient; D: Donor; LT: Liver transplant; Lam: Lamivudine; Adef: Adefovir.
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ticenter studies are required to confirm our findings.
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